# Nexgel, Inc.: overview

NXGL · Nasdaq · CIK 1468929 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nxgl.md) · [Financials](/companies/nxgl/financials.md) · [Filings](/companies/nxgl/filings.md) · [Insiders](/companies/nxgl/insiders.md)

Latest reported revenue: [$3.7m](/filings/0001493152-26-038555.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 17, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-038555).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,940](/filings/0001493152-25-021738.md) | [3,041 d](/filings/0001493152-26-014377.md) | [2,806](/filings/0001493152-26-023207.md) | [2,884](/filings/0001493152-26-038555.md) | [2,934](/filings/0001493152-25-021738.md) | [2,796 d](/filings/0001493152-26-014377.md) | [2,650](/filings/0001493152-26-023207.md) | [3,686](/filings/0001493152-26-038555.md) |
| Gross margin | % | [39.3%](/filings/0001493152-25-021738.md) | [35.3% d](/filings/0001493152-26-014377.md) | [42.3%](/filings/0001493152-26-023207.md) | [43.6%](/filings/0001493152-26-038555.md) | [42.4%](/filings/0001493152-25-021738.md) | [29.3% d](/filings/0001493152-26-014377.md) | [40.0%](/filings/0001493152-26-023207.md) | [30.1%](/filings/0001493152-26-038555.md) |
| Operating margin | % | [(26.8%)](/filings/0001493152-25-021738.md) | [(27.7%) d](/filings/0001493152-26-014377.md) | [(27.7%)](/filings/0001493152-26-023207.md) | [(22.1%)](/filings/0001493152-26-038555.md) | [(24.7%)](/filings/0001493152-25-021738.md) | [(43.4%) d](/filings/0001493152-26-014377.md) | [(36.2%)](/filings/0001493152-26-023207.md) | [(68.0%)](/filings/0001493152-26-038555.md) |
| Net margin | % | [(23.6%)](/filings/0001493152-25-021738.md) | [(28.0%) d](/filings/0001493152-26-014377.md) | [(25.4%)](/filings/0001493152-26-023207.md) | [(23.1%)](/filings/0001493152-26-038555.md) | [(22.3%)](/filings/0001493152-25-021738.md) | [(34.7%) d](/filings/0001493152-26-014377.md) | [(35.0%)](/filings/0001493152-26-023207.md) | [(98.6%)](/filings/0001493152-26-038555.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001493152-25-021738.md) | not reported | [(0.09)](/filings/0001493152-26-023207.md) | [(0.09)](/filings/0001493152-26-038555.md) | [(0.08)](/filings/0001493152-25-021738.md) | not reported | [(0.11)](/filings/0001493152-26-023207.md) | [(0.40)](/filings/0001493152-26-038555.md) |
| Free cash flow | $k | [(1,229) d](/filings/0001493152-25-021738.md) | [(928) d](/filings/0001493152-26-014377.md) | not reported | not reported | [(793) d](/filings/0001493152-25-021738.md) | [241 d](/filings/0001493152-26-014377.md) | [(513)](/filings/0001493152-26-023207.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.6](/filings/0001493152-23-009190.md) | [2.0](/filings/0001493152-24-014127.md) | [4.1](/filings/0001641172-25-000937.md) | [8.7](/filings/0001493152-26-014377.md) | [11.4](/filings/0001493152-26-014377.md) |
| Gross margin | % | [0.5%](/filings/0001493152-23-009190.md) | [12.5%](/filings/0001493152-24-014127.md) | [9.1%](/filings/0001641172-25-000937.md) | [31.6%](/filings/0001493152-26-014377.md) | [39.5%](/filings/0001493152-26-014377.md) |
| Operating margin | % | [(165.7%)](/filings/0001493152-23-009190.md) | [(163.5%)](/filings/0001493152-24-014127.md) | [(85.0%)](/filings/0001641172-25-000937.md) | [(40.9%)](/filings/0001493152-26-014377.md) | [(29.3%)](/filings/0001493152-26-014377.md) |
| Net margin | % | [(277.9%)](/filings/0001493152-23-009190.md) | [(231.7%)](/filings/0001493152-24-014127.md) | [(77.2%)](/filings/0001641172-25-000937.md) | [(37.8%)](/filings/0001493152-26-014377.md) | [(26.3%)](/filings/0001493152-26-014377.md) |
| Diluted EPS | $ per share | [(1.45)](/filings/0001410578-22-000442.md) | [(0.85)](/filings/0001493152-24-014127.md) | [(0.56)](/filings/0001641172-25-000937.md) | [(0.50)](/filings/0001493152-26-014377.md) | [(0.38)](/filings/0001493152-26-014377.md) |
| Free cash flow | $m | [(3.0)](/filings/0001493152-23-009190.md) | [(3.1)](/filings/0001493152-24-014127.md) | [(3.9)](/filings/0001641172-25-000937.md) | [(4.3)](/filings/0001493152-26-014377.md) | [(1.4)](/filings/0001493152-26-014377.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nxgl/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $21.2k | 550,000 |  | Unchanged |
| [Warberg Asset Management LLC](/funds/1597506.md) | 2026-06-30 | $4.7k | 145,591 |  | Reduced −500 |
| [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $3.5k | 90,000 |  | Unchanged |
| [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $2.0k | 50,814 |  | Added +200 |
| [TWO SIGMA SECURITIES, LLC](/funds/1450144.md) | 2026-06-30 | $584 | 21,875 |  | New +21,875 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $407 | 15,081 |  | Reduced −1,000 |

## Recent filings

[All 327 filings](/companies/nxgl/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-07 | 20:39 ET | [8-K](/filings/0001493152-26-046154.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-046154 |
| 2026-09-24 | 20:15 ET | [8-K](/filings/0001493152-26-044149.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-044149 |
| 2026-09-23 | 21:20 ET | [8-K](/filings/0001493152-26-043955.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-043955 |
| 2026-08-24 | 21:14 ET | [DEF 14A](/filings/0001493152-26-039890.md) | Proxy statement, period 2026-08-24 | 0001493152-26-039890 |
| 2026-08-21 | 20:42 ET | [8-K](/filings/0001493152-26-039708.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-039708 |
| 2026-08-20 | 16:39 ET | [S-1](/filings/0001493152-26-039421.md) | Registration statement | 0001493152-26-039421 |
| 2026-08-17 | 12:15 ET | [8-K](/filings/0001493152-26-038637.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-038637 |
| 2026-08-17 | 23:40 ET | [10-Q](/filings/0001493152-26-038555.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038555 |
| 2026-08-05 | 21:00 ET | [8-K](/filings/0001493152-26-036206.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-036206 |
| 2026-07-29 | 21:25 ET | [8-K](/filings/0001493152-26-035258.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-035258 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014377.md), filed Mar 31, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bbe357d2-5b99-466e-83a6-e34024758ee0)

## About the filer

- CIK: 1468929
- Tickers: NXGL, NXGLW
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.